期刊文献+

甲磺酸伊马替尼治疗慢性粒细胞白血病引起男性乳房女性化1例报道 被引量:1

Imatinib mesylate caused gynaecomastia in treatment of chronic myelocytic leukemia:a case report
原文传递
导出
摘要 1病例资料 患者,男,60岁,于2003年5月起无明显诱因下自觉劳累伴消瘦,未诊治,后2004年3月因"胃痛、发热、黑便、呕吐咖啡色液体"至我院消化科就诊,查血常规: Imatinib mesylate is the first-line drug in treatment of chronic myelocytic leukemia(CML),which has an epoch-making milestone significance in the treatment of CML and is the preferred drug for the treatment of CML worldwide.However,it also has many common adverse reactions.Recently,we have found a rare case that an old man had gynaecomastia after taking imatinib mesylate for 20 months.The author writes this report in order to attract the medical workers' attention to such adverse reactions of imatinib mesylate.
作者 石岭 王运律
出处 《临床血液学杂志》 CAS 2015年第1期69-70,共2页 Journal of Clinical Hematology
关键词 白血病 粒细胞 慢性 甲磺酸伊马替尼 男性乳房女性化 chronic myelocytic leukemia imatinib mesylate gynaecomastia
  • 相关文献

参考文献7

二级参考文献37

  • 1QDWYER M E.DRUKER B J. Recent advancementsin the treatment of chronic myelogenous leukemia[J].Blood,2002,53:369_ 381.
  • 2JEMAL A,SIEGEL R, XU J, et al. Cancer statistics,2010[J]. CA Cancer J Clin,2010 ,60:277 - 300.
  • 3WHITE D L,SAUNDERS V A,DANQ P,et al. OCT-1-mediated influx is a key determinant of the intracel-lular uptake of imatinib but not nilotinib( AMN107):reduced OCT-1 activity is the cause of low in vitrosensitivity to imatinib[J]. Blood,2006,108 : 697 - 704.
  • 4HOCHHAUS A,OBRIEN S G’GUILHOT F,et al.Six-year follow-up of patients receiving imatinb for thefirst-line treatment of chronic myeloid leukemia [J].Leukemia’ 2009,23 : 1054-1061.
  • 5DRUKER B J,GUILHOT F, O'BRIEN S G, et al.Five-year follow-up of patients receving Imatinib forchronic myeloid leukemia [J]. N Engl J Med, 2006,355:2408 - 2417.
  • 6RADICH J. Stem cell transplantation for chronic mye-loid leukemia in the imatinib era[J]. Semin Hematol.2010,47..354-361.
  • 7DEININGER M,OBRIEN S G,FRANCOIS G,et al.International randomized study of interferon VsSTI571 ( iris) 8-year follow up: sustained survival andlow risk for progression or events in patients withnewly diagnosed chronic myeloid leukemia in chronicphase ( CML-CP ) treated with imatinib [ J ]. Blood(ASH Annual Meeting Abstracts) , 2009,114*1126.1126.
  • 8VENEPALLI N,REZVANI K,MIELKE S,et al. Roleof allo-SCT in CML in 2010[J]. Bone Marrow Trans-plant, 2010,45 : 1579-1586.
  • 9HUGHES T P, HOCHHAUS A’SAGLIO G,et al.ENESTnd update: continued superiority of nilotinibversus imatinib in patients with newly diagnosed chro-nic myeloid Leukemia in chronic.phase(CML-CP)0].Blood, 2010,116 :207-207.
  • 10HOCHHAUS A.SAGLIO G, LARSON R A,et al.Nilotinib lowers the incidence of BCR-abl mutationsand improves the molecular response kinetics com-pared with imatinib in patients(Pts) with newly diag-nosed chronic myeloid leukemia ( CML) [ J]. Blood,2010,116:3431-3431.

共引文献9

同被引文献3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部